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e-mail address: syiu2@jhmi.edu (S.C. Yiu).Pho Nguyen, MD a; Kelly Rue, MD a; Martin Heur, MD, PhD a; Samuel C. Yiu, MD, PhD b,⇑AbstractBackground: Human amniotic membrane is a versatile tool for management of ocular surface disorders. This study evaluates the
effect of cryopreserved human amniotic membrane (hAM) on one-year survival of penetrating keratoplasties (PKP) in high-risk
recipients.
Method: This is a retrospective noncomparative cohort study of 58 consecutive eyes undergoing PKP with concurrent placement
of a self-retained cryopreserved hAM (PROKERA) at a tertiary care center from January 2009 to July 2010.
Results: Mean patient age was 66.7 ± 17.2 years and 30 (54%) were males. 51 eyes were pseudophakic and one aphakic. 27 eyes
were glaucomatous; 24 had glaucoma drainage device and 2 had previous endocyclophotocoagulation. 12 patients had PKP for
the first time and 46 had repeat PKP (average number of prior PKP = 1.63 ± 1.1, range: 1–5).
Risk factors for graft failure included repeat PKP (79.3%), corneal neovascularization (51.7%), preexisting glaucoma (46.6%), and
presence of anterior synechiae (37.9%). Both First Transplant and Repeat Transplant groups had similar survival rates until
6 months after transplant (75% vs 74%, odds ratio = 1.06, p = 1.00). At 12 months, First Transplant group showed a better survival
rate (67% vs 43%, odds ratio = 2.60, p = 0.20). Eyes with >3 risk factors had a higher graft failure rate (odds ratio = 5.81,
p = 0.003).
Conclusion: Survey of the literature suggests that high-risk PKP with concurrent hAM placement demonstrate comparable graft
survival. Presence of multiple risk factors is associated with poor survival.
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The human amniotic membrane (hAM) has become a ver-
satile tool in the management of ocular surface disorders. It is
the inner most layer of the placenta, consisting of the mater-
nal outer chorion and the fetal inner amnion. The hAM is
comprised of a monolayer epithelium, a basement mem-
brane, and an avascular stromal matrix. Initial indication was
reported by De Rotth in 1940 for repair of conjunctivaldefects;1 in the late 20th and early 21st centuries, the indica-
tions for hAM transplant rapidly expanded, as investigators
discovered that the immunologically naïve hAM plays impor-
tant roles in wound healing.
The unique properties of hAM are amply documented in
the literature. It has been demonstrated to reduce the inflam-
matory response, induce suppression of interleukin alpha and
interleukin 1 beta in epithelial cells,2–6 support survival of the
transplanted limbal epithelial stem cells via growth factors,7e:
al.com
y/Smith
Use of amniotic membrane in high-risk penetrating keratoplasties 199and via clearance of polymorphonuclear cells and inhibition
of proteinase activity.8,9 Induction of apoptosis of T lympho-
cytes and modulation of activated macrophages by hAM were
found to play important roles in tissue remodeling.10–14 Insults
to the ocular surface, such as surgeries, trauma, or burns, may
potentiate deleterious cascades resulting in decreased vision
and patient comfort. The hAM has been shown to reduce
scar tissue formation by trapping and preventing polymor-
phonuclear infiltration into the corneal stroma15 and by
downregulation of the transforming growth factor beta sig-
naling system and myofibroblast differentiation of normal
fibroblasts.16,17 Other groups explored the utility of hAM as
a bioactive substrate in limbal stem cell expansion and
transplantation with varying results.18–23 Interestingly, the
anti-inflammatory activities and modulation of macrophages
have been replicated in water-soluble hAM extract,24
cryopreserved hAM tissue,25 and a covalent complex of
hyaluronan and the heavy chain of inter-a-inhibitor purified
from hAM extract,26 greatly expanding the versatility
of hAM.
Presently, there are various commercially available pre-
served hAMs for ophthalmic applications. Bio Tissue Inc.
(Doral, FL, USA) provides AmnioGraft, AmnioGuard™, and
PROKERA via cryopreservation method. IOP Ophthalmics
Inc. (Costa Mesa, CA, USA) supplies the free-dried alterna-
tives, Ambio2™, Ambio5, and AmbioDisk™. Recently,
lyophilized extract of the fresh hAM (AMX), prepared by
Keera srl and distributed by Treviso Tissue Bank, Italy, has
been made available in Europe. However, the literature on
AMX efficacy is rather scant.27 Table 1 compares these
tissues.
Although utility of hAM is widely reported for many ocular
surface applications,28,29 its use in corneal transplant is lim-
ited. Despite the fact that corneal transplantation is now
the most successful human organ transplantation, routinely
performed without HLA typing or systemic immunosuppres-
sion, the long-term success of penetrating keratoplasty
(PKP) is dictated by risk factors.30–38 Having multiple risk
factors, such as preoperative diagnosis of corneal opacity,
corneal neovascularization, presence of anterior synechiae,
prior rejection, coexisting glaucoma, and recipient gender
and age at time of transplant, predisposes the patient to
graft rejection and failure.39–50 Data from the literature sug-
gest that topical steroids may be inadequate for high-risk
recipients, systemic steroids and immunomodulatory thera-
pies pose significant adverse effects, and newer therapeutic
strategies are being explored to improve survival of high-risk
transplants.51–60Table 1. Comparison of commercially available preserved human amniotic mem
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Availability Worldwide WorldwideThe unique properties of hAM suggest that it may be an
adjuvant therapy to reduce the risks of graft rejection in
high-risk PKP. Accordingly, we set forth to investigate
whether high-risk PKP recipients would benefit from hAM
placement. In this retrospective series, we evaluate the failure
rates of PKP when performed in conjunction with cryopre-
served hAM placement in patients with high-risk features
and compare our graft failure rates to those reported in the
literature.30,34,44–50
Materials and methods
The study population consisted of 58 eyes of 56 patients
who underwent PKP with placement of self-retained hAM
devices (PROKERA, Bio-Tissue, Inc., Doral, FL). PROKERA
is a class II medical device comprised of cryopreserved
hAM clipped into a dual polymethyl methacrylate symbleph-
aron ring system, where the stromal aspect is in contact with
the corneal epithelium. It was selected because its placement
can be performed without sutures and bioadhesives, reduc-
ing confounding factors. A retrospective chart review was
conducted for demographics and pre- and post-operative
findings. The main outcome measure was clinical determina-
tion of graft failure. Study protocol was approved by the
Institutional Review Board; and strict adherence to the princi-
ples of the Declaration of Helsinki was followed.
All surgeries and preoperative/postoperative cares were
performed by a single surgeon (SCY). Briefly, the donor but-
ton was prepared using a Barron punch and coated with vis-
coelastic device for protection. A Hessburg-Barron vacuum
trephine and corneal scissors were used to excise the host
corneal button. The graft was secured to the host bed with
interrupted 10-0 nylon sutures; subsequently, ophthalmic vis-
coelastic device was irrigated and the anterior chamber was
reformed with balanced salt solution. All suture knots were
buried. Subconjunctival injections of cefazolin, tobramycin,
and dexamethasone were given. Thereafter, a self-retained
amniotic membrane device was placed over the corneal but-
ton. Postoperative care for these patients was provided by
the same surgeon, and included standard regimen of antibi-
otic and steroid drops, as well as follow-up visits at post-
operative (PO) day 1, PO week (POW) 1, PO month (POM)
1, POM 3, 6, 9 and 12.
Inclusion criteria were eyes with at least 12-month post-
operative follow-up visits and having two or more risk factors
for graft rejection and failure,5–9,36 identified preoperatively.
Risk factors are high-risk indications for transplant, corneal
stromal neovascularization of two or more quadrants, historybrane for ophthalmic applications.
Keera, srl
preserved Lyophilized extract of the
fresh human amniotic
membrane
ellulose paper, cryopreserved at
2 years
Soluble powder form, stored
in dry environment at 18–
20 C
perature before use Dilution with sterile BSS
ure fixation for AmnioGraft and
lf-retained symblepharon ring for
Topical using eye drop
dispenser
Europe
Table 3. Concurrent surgical interventions.
Additional intervention # of
Patients
Synechiolysis 5
Synechiolysis + intraocular lens placement 1
Cataract extraction/intraocular lens placement 3
Secondary intraocular lens placement or exchange 2
Iridoplasty 1
Anterior vitrectomy 1
Glaucoma drainage implant 1
Temporary keratoplasty, vitrectomy, glaucoma
drainage implant, intraocular lens exchange
1
200 P. Nguyen et al.of anterior segment inflammation, presence of anterior syn-
echiae, glaucomatous eyes on medication or had glaucoma
drainage implant (GDI) placement, severe ocular surface dis-
orders such as limbal stem cell deficiency, ocular cicatricial
pemphigoid, severe dry eye, and age less than 40 years.
High-risk indications for transplant were prior graft failure,
pseudophakic or aphakic bullous keratopathy, corneal perfo-
ration, or herpetic keratitis with visually significant corneal
scar. Only patients receiving surgeries during the period of
June 2009 to July 2010 and having one-year follow-up were
included.Results
Fifty-eight eyes met the inclusion criteria; nine patients
were excluded due to insufficient follow-up. Preoperative
demographics are tabulated in Table 2. Mean age was
66.7 ± 17.2 years and 30 patients (51.7%) were male. 51 eyes
(88%) were pseudophakic and one (1.8%) was aphakic. 27
eyes were glaucomatous; 24 of these had GDIs and 2 had
endocyclophotocoagulation performed for poorly controlled
glaucoma. Twelve eyes received corneal transplants for the
first time (First Transplant). Forty-six eyes received repeat
PKP (Repeat Transplant). The average number of prior PKP
was 1.63 ± 1.1 (range: 1–5). Indications for initial PKP included
corneal scar (4), endothelial failure (3), microbial keratitis with
perforation or visually significant corneal scar (5). Corneal
neovascularization of two or more quadrants was observed
in 30 eyes (51.7%) and presence of anterior synechiae existed
in 22 eyes (37.9%). The mean numbers of risk factors for graft
rejection were 3.0 ± 0.74 for the first PKP group and
3.6 ± 1.02 for the repeat PKP group. Fifteen patients received
another concurrent surgery at the time of PKP (Table 3).
Overall one-year survival rate was 52%. At postoperative
month six, both the First Transplant and Repeat Transplant
groups showed similar survival rates (75% versus 74%, odds
ratio (OR) = 1.06, p = 1.00). At twelve months, the First
Transplant group appeared to have a better survival (67%),
compared to that of the Repeat Transplant group (43%). This
advantage did not reach statistical significance using univari-
ate analysis (OR = 2.60, p = 0.20).
Univariate analysis was performed to calculate the odds
ratios of graft failure for selected risk factors (Table 4). No
significantly increased risks of failure were observed when
comparing First Transplant versus Repeat Transplant
(OR = 0.38, p = 0.20). Recipient corneal neovascularization
equal to or greater than 2 quadrants was associated with
increased risk of rejection but statistical significance was
not achieved (OR = 2.0, p = 0.29). However, the OR of graftTable 2. Patient demographics and preoperative clinical characteristics.
Patient characteristics Count Percentage (%)
Age (years) 66.4 ± 17.4
Gender (male) 30 52
High-risk indications 58 100
Corneal neovascularization 30 52
Herpetic keratitis 7 12
Anterior segment inflammation 12 21
Anterior synechiae 22 38
Ocular surface disorder 10 17
Glaucoma 27 47
Age <40 4 7
Pseudophakia or aphakia 52 90
Prior vitreoretinal surgery 5 9rejection increased to 5.81 (p = 0.003) when eyes with three
or less risks factors were compared to eyes with more than
three risks factors. Overall, eyes receiving concurrent intraoc-
ular surgery as tabulated in Table 2 did not show increased
risks of rejection (OR = 1.31, p = 0.767). Interestingly, eyes
undergoing synechiolysis had a rejection rate of 83% and
appeared to be associated with increased risk of rejection
(OR = 5.20, p = 0.197).
Discussion
This present study evaluates the role of human amniotic
membrane for prevention of graft rejection in high-risk pene-
trating keratoplasties. The idea is to leverage the inflamma-
tory modulation activities of hAM to suppress graft
rejection, as it is the leading cause of graft failure.34 High-risk
features have been associated with a 30–56% risk of graft fail-
ure at 3 years.46 Prior studies reported the poor prognostic
value of vascularization of recipient bed.37,40–42 Indeed, a
meta-analysis of 19 studies encompassing 24,944 grafts con-
cluded that presence of recipient neovascularization
increases the risk of future graft failure by 30% and more than
doubles the risks of graft rejection.37 We also found a 60%
failure rate in host bed having two or more quadrants of cor-
neal neovascularization, which was elevated compared to
non-neovascularized host. Other studies found that glau-
coma, intraocular inflammation, younger age35,37 or vitrec-
tomy performed at time of transplant38,48 were associated
with increased risk of failure. Our study corroborated these
findings but we lack statistical power due to small sample size
of patients having many high-risk features.
As expected, failed PKP is a poor prognosticator. In a ret-
rospective study, Bersudsky and colleagues published failure
rates of 63% in first regrafts that increased to 75–100% in
third and fourth regrafts.42 Yildiz et al. followed 45 patients
over 6 years and reported a five-year graft failure rate of
53–64% in third and fourth grafts.36 More recently, Fasolo
and colleagues calculated a failure rate of 42.8%, with a med-
ian time to failure of 2.3 years in regrafts related to allograft
rejection.38 In our study, 87% (26 of 30) of the eyes that
developed graft failure had prior failed transplants. These
high-risk patients were expected to have substantial neovas-
cularization and likely immune activation resulting from previ-
ously failed transplants.34 The lower survival rates in our
cohort, 67% for first transplants and 43% for the regrafts,
may be the result of a different patient population with
higher number of risk factors, 3.0 ± 0.74 in First Transplant
group and 3.6 ± 1.02 for the Repeat Transplant group.
Indeed, univariate analysis substantiated that having more
than three preoperative risk factors significantly decreased
graft survival.
Table 4. 12-month failure rates for each individual risk factor.
Risk factors Failure rate (%) Odds ratio p-Value 95% confidence interval
First transplant 33.3
Repeat transplant 56.5 2.6 0.20 0.10–1.46
Glaucoma 55.6 1.3 0.61 0.47–3.76
Corneal neovascularization (P2 quadrants) 60.0 2.0 0.29 0.70–5.70
Herpetic corneal scar 14.3 0.1 0.048 0.01–1.13
Prior anterior uveitis 58.3 1.4 0.75 0.39–5.06
Presence of anterior synechiae 63.6 2.2 0.18 0.74–6.50
3+ risk factors 71.0 5.8 0.003 0.06–0.54
Concurrent intraocular surgery 46.7 1.3 0.77 0.40–4.27
Synechiolysis 83.3 5.4 0.20 0.59–49.5
Use of amniotic membrane in high-risk penetrating keratoplasties 201Interestingly, having concurrent intraocular surgeries did
not significantly increase the rate of graft rejection. However,
synechiolysis was associated with increased risk of graft failure.
It is likely that anterior synechiae is an indicator for prior intra-
ocular inflammation, prior surgery, trabecular meshwork com-
promise, or anatomic predisposition, that translate to surgical
difficulty, increased risks of complications, or altered anterior
chamber-associated immune deviation. Iris synechiae to the
graft or host-graft junction may further facilitate antigen pre-
sentation and sensitization.43,46 Thus, the correlation between
synechiolysis and graft rejection was not unexpected.
Many limitations are evident in this retrospective study.
Two critical limitations were the lack of controls and inade-
quate power for meaningful statistical analysis. Additionally,
our cohort consisted of high-risk population, as shown in
Tables 2 and 3, which prohibited direct comparison with the
data reported in the literature. Therefore, we were unable to
draw a definitive conclusion regarding the benefits of adjunc-
tive cryopreserved human amniotic membrane placement, in
the form of the PROKERA device, in high-risk penetrating
keratoplasty. This might be related to the limited efficacy of
hAM on the ocular surface in suppressing stromal or endothe-
lial immunogenic cascades. Further studies are encouraged to
definitely address the role of hAM in high-risk PKP.
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